AND017 vs SSS17

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

AND017

Developed by Kind Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT05265325 · Phase 2 · completed

The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07494409 (registry estimate)

No aligned efficacy figure on record for this race.

SSS17

Developed by Shenyang Sunshine Pharmaceutical

Phase 2 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT07014631 · Phase 2 · completed

The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAND017SSS17
Kidney composite outcome—Trial running · NCT07487727—Not reported
UACR, % change—Trial running · NCT07487727—Not reported
eGFR slope—Trial running · NCT07487727—Not reported
Haemoglobin, change—Trial running · NCT07487727—Not reported

Kidney composite outcome

AND017
—Trial running · NCT07487727
SSS17
—Not reported

UACR, % change

AND017
—Trial running · NCT07487727
SSS17
—Not reported

eGFR slope

AND017
—Trial running · NCT07487727
SSS17
—Not reported

Haemoglobin, change

AND017
—Trial running · NCT07487727
SSS17
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AND017: no structured comparison results are available for Chronic Kidney Disease.

SSS17: no structured comparison results are available for Chronic Kidney Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · SSS17's landscape